ANTERIS TECHNOLOGIES LTD (ASX:AVR) - Competitor - JenaValve, page-6 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by Investek: ↑

Thanks HuonScott.

I mentioned in another post that I am now doing a bit more homework to better understand what AHZ is worth as a TAVR/structural heart company, competitor analysis is just part of the process (if only I did my homework
before investing!)

I have a slightly different take on in (re: it's not what we want to see at the moment). Sure there is competition however it shows me there is no shortage of money to be invested in this space. Why AHZ needed to go to the equivalent of loan sharks for funding rather than these types of strategic long term investors is beyond me. The only thing I can thing of is that a portion of them would have a mandate to invest only in private companies.

As for why AHZ's product is superior Patto has stated a few of these reasons single piece valve (^durability), ADAPT tissue (anti-calcification), catheter size (I cant recall ? French not sure it was much smaller than current competitors), sterile packaging (reduced prep/op time), and he stated something around the haemodynamics (I cant recall figures).

From the tiny bit of proper research I've done, the main differentiator (value driver) I can see at present is durability. Reading some comments from TVT 2019 (the structural heart conference) durability of TAVR devices was a concern raised by several/many? surgeons (and not just those on the AHZ advisory board).

I recall from the mechanical testing of the prototype valve vs some competitor's valves, that AHZ's performed better (suffered less degradation?) however I can't remember seeing many specifics about degree of wear and tear to any/all of the valves tested.

This gives me some hope for AHZ and their TAVR however still a way to go, further testing in man, larger trial (inc. appropriate design), FDA approval, need to win market share from incumbents (and we saw how difficult that was with ADAPT!).

Part of the reason for posting this info on JenaValve is to get a more realistic idea of both potential company value and to better understand the costs and timeline involved.

An opportunity I see is that if (and its a big if) AHZ can design and execute a trial to demonstrate far greater durability of their valve vs the major competitors, the company may have a real chance/bright future. With my limited knowledge I believe this would need to be an in-human trial and would need to show statistically significant (i.e. p<0.05) improvement in durability. I'm not sure how you do this in less than 10 years... (and without the cash to stay in business for another 10 years). Maybe surgeons would take notice of results from another mechanical test if the trial was designed very well and the results written up/approved in the most prestigious Cardiac journal? (However this approach may not work as the simulator may not be seen as representative enough of human use conditions?)

I just don't know enough (yet) to make an intelligent call on all this.

Cheers,
Investek

Expand

Hi Investek,

A couple of links to get you on your way;

An up-to-date overview of the most recent transcatheter implantable aortic valve prostheses
https://www.tandfonline.com/doi/pdf/10.1586/17434440.2016.1120665

Principles of TAVR Valve Design, Modelling, and Testing
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417919/pdf/nihms-1520139.pdf

We await news of the Admedus human trials with baited breath.

No.	Vol.	Price($)
1	60	$17.88

No.

Vol.

Price($)

$17.88

Price($)	Vol.	No.
$18.05	554	1

Price($)

Vol.

No.

$18.05

554

No.	Vol.	Price($)
1	60	17.880
1	47	17.870
1	619	17.860
1	37	17.650
2	700	17.550

No.

Vol.

Price($)

17.880

17.870

619

17.860

17.650

700

17.550

Price($)	Vol.	No.
18.050	554	1
18.100	1000	1
18.200	343	2
18.300	150	1
18.500	43	1

Price($)

Vol.

No.

18.050

554

18.100

1000

18.200

343

18.300

150

18.500

(20min delay)
Last $17.97		Change -0.235(1.29%)		Mkt cap ! $345.3M

Open	High	Low	Value	Volume
$18.09	$18.09	$17.88	$1.182K	66

Competitor - JenaValve, page-6

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

American West does it again at Storm with visually identified thick copper hits at Cyclone, Lightning Ridge

Greentech finds lithium trend across 5.5 km at WA's Kobe South

Legacy shares jump on discovery of multiple epithermal veins at Bauloora JV

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Competitor - JenaValve, page-6

Top Stories

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

American West does it again at Storm with visually identified thick copper hits at Cyclone, Lightning Ridge

Greentech finds lithium trend across 5.5 km at WA's Kobe South

Legacy shares jump on discovery of multiple epithermal veins at Bauloora JV

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News